RUBINSTEIN JULIE sold $897K of ADPT

RUBINSTEIN JULIE (President and COO) sold 35,643 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $25.18 ($24.38–$26.30, $0.90M total) across 6 trades over 2026-10-22 to 2026-10-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RUBINSTEIN JULIE
Published Oct 26, 2026, 10:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 10:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ADPT
Bearish
medium confidence
Mentioned
$ADPT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADPTBearishLow
01

Why it matters

The disclosed sale may prompt short‑term price weakness but likely has limited long‑term effect.

02

Market read

Insider sale of ~$0.9M by a senior executive; modest relevance for traders monitoring ADPT.

03

What to watch

Potential upcoming regulatory or clinical milestones that may offset the sell‑off.

Relevance 4/10Novelty 4/10Timing: after filing today

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan allows pre‑scheduled sales.

Company-level read

Ticker impact

$ADPTBearishMedium confidence
Context

President and COO Julie Rubinstein sold 35,643 shares for $897K via a 10b5-1 plan, reducing her stake to 377,802 shares.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A sizable insider sale by a top executive, even via a pre‑arranged plan, often triggers short‑term selling pressure.

Market effects

Minimal impact on the broader biotech sector; the sale is company‑specific.

No regional effect; confined to US markets.

Limited global relevance; only affects Adaptive Biotechnologies investors.

Counterpoint

The sale could be purely procedural under the 10b5‑1 plan, not reflecting negative sentiment.

Key entities

  • Julie Rubinstein

    President and COO of Adaptive Biotechnologies

  • Adaptive Biotechnologies Corp

    US‑listed biotech firm (NASDAQ: ADPT)

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ADPTHigh

Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive (ADPT) raised its 2026 MRD revenue guidance due to strong clinical volumes and pharma revenue. Q3 saw 46% YOY growth in clinical testing volume, with 41% growth in clinical revenue. The company earned a milestone payment from Pfizer and is advancing its immune medicine separation process. Blood-based testing and community adoption of clonoSEQ increased significantly. U.S. ASP was $1,380 in Q3, with coverage gains in DLBCL and MCL.

$ADPTHigh

Adaptive Biotechnologies Corp (ADPT) Q3 2026 Earnings Call Highlights: First Profitable

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. US ASP was $1,380, flat sequentially. The company expects no GAAP net income for Q4 or the full year. Challenges include Medicare payment structures and CMS rate uncertainties. Management remains confident in long-term pricing strategy and growth, citing favorable guidelines and market expansion.

$ADPTMedAI 8/10

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies (ADPT) reported Q3 2026 revenue of $83.9M, up 39% YoY, with GAAP net income of $2.8M. The company raised its full-year MRD revenue outlook to $276M-$286M. Clinical testing volume increased 46% YoY, and clonoSEQ tests grew 10% sequentially. Adaptive expects 42% clinical volume growth for the year and is pursuing Medicare reimbursement updates.